Association between C-peptide concentration and prostate cancer incidence in the CLUE II cohort study

Cancer Prevention Research

Volumn 3, Issue 10, 2010, Pages 1334-1341

  Lai, Gabriel Y ^a   Helzlsouer, Kathy J ^a,b,c   Clipp, Sandra L ^a   Rifai, Nader ^e   Platz, Elizabeth A ^a,c,d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b MERCY MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERINSULINEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; C-PEPTIDE; CASE-CONTROL STUDIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPERINSULINISM; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; OBESITY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 77958563497     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0053     Document Type: Article

References (38)

1. Hsing AW, Sakoda LC, Chua S, Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007;86:s843-57.
2. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006;17:989-1003.
3. Freedland SJ, Giovannucci E, Platz EA. Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control 2006;17:5-9.
4. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007;132:2208-25. (Pubitemid 46693749)
5. Nandeesha H. Insulin: a novel agent in the pathogenesis of prostate cancer. Int Urol Nephrol 2009;41:267-72.
6. Cox ME, Gleave ME, Zakikhani M, et al. Insulin receptor expression by human prostate cancers. Prostate 2009;69:33-40.
7. Hsing AW, Chua S, Jr., Gao YT, et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001;93:783-9.
8. Stattin P, Soderberg S, Hallmans G, et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 2001;86:1341-5. (Pubitemid 32323026)
9. Hubbard JS, Rohrmann S, Landis PK, et al. Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology 2004;63:253-8. (Pubitemid 38234413)
10. Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 2005;103:76-84. (Pubitemid 39665459)
11. Neuhouser ML, Till C, Kristal A, et al. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res 2010; 3:279-89.
12. Borugian MJ, Spinelli JJ, Sun Z, et al. Prediagnostic C-peptide and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16: 2164-5. (Pubitemid 47621196)
13. Stocks T, Lukanova A, Rinaldi S, et al. Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer 2007;120:2678-86. (Pubitemid 46651291)
14. Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008;9:1039-47.
15. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15:2056-62.
16. Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006;15:1977-83.
17. Calton BA, Chang SC, Wright ME, et al. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 2007;18:493-503. (Pubitemid 46684823)
18. Velicer CM, Dublin S, White E. Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications. Prostate Cancer Prostatic Dis 2007;10:46-51. (Pubitemid 46358910)
19. Darbinian JA, Ferrara AM, Van Den Eeden SK, Quesenberry CP, Jr., Fireman B, Habel LA. Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2008;17:628-35. (Pubitemid 351469213)
20. Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 2009;124:1398-403.
21. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 2009;169:937-45.
22. Kasper JS, Liu Y, Pollak MN, Rifai N, Giovannucci E. Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes Control 2008;19:703-10.
23. Bonser AM, Garcia-Webb P. C-peptide measurement: methods and clinical utility. Crit Rev Clin Lab Sci 1984;19:297-352.
24. Hovorka R, Jones RH. How to measure insulin secretion. Diabetes Metab Rev 1994;10:91-117.
25. Block G, Hartman AM, Dresser CM, Carroll MD, Gannon J, Gardner L. A data-based approach to diet questionnaire design and testing. Am J Epidemiol 1986;124:453-69. (Pubitemid 16047362)
26. Christlieb AR, Krolewski AS, Warram JH, Soeldner JS. Is insulin the link between hypertension and obesity? Hypertension 1985;7: 1154-7.
27. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106:473-81.
28. Lazarus R, Sparrow D, Weiss S. Temporal relations between obesity and insulin: longitudinal data from the Normative Aging Study. Am J Epidemiol 1998;147:173-9. (Pubitemid 28060489)
29. Manicardi V, Camellini L, Bellodi G, Coscelli C, Ferrannini E. Evidence for an association of high blood pressure and hyperinsulinemia in obese man. J Clin Endocrinol Metab 1986;62:1302-4. (Pubitemid 16085296)
30. Hsing AW. Hormones and prostate cancer: what's next? Epidemiol Rev 2001;23:42-58.
31. Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 2004;92:237-53.
32. Baillargeon J, Pollock BH, Kristal AR, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005;103:1092-5.
33. Barqawi AB, Golden BK, O'Donnell C, Brawer MK, Crawford ED. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology 2005;65: 708-12.
34. Werny DM, Thompson T, Saraiya M, et al. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev 2007;16:70-6.
35. Fowke JH, Matthews CM, Buchowski MS, et al. Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men. Prostate Cancer Prostatic Dis 2008;11:264-9.
36. Parekh N, Lin Y, Marcella S, Kant AK, Lu-Yao G. Associations of life-style and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (2001-2004). Cancer Epidemiol Biomarkers Prev 2008;17: 2467-72.
37. Sundell IB, Hallmans G, Nilsson TK, Nygren C. Plasma glucose and insulin, urinary catecholamine and cortisol responses to test breakfasts with high or low fibre content: the importance of the previous diet. Ann Nutr Metab 1989;33:333-40.
38. von Post-Skagegard M, Vessby B, Karlstrom B. Glucose and insulin responses in healthy women after intake of composite meals containing cod-, milk-, and soy protein. Eur J Clin Nutr 2006;60: 949-54.